We therefore also show that manipulating mitochondrial and glycolytic bioenergetic pathways in smn morphant zebrafish can ameliorate SMA phenotypes, implicating these pathways as potential therapeutic targets. The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.